Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys and BioGen Ink Genomics Collaboration

NEW YORK, Jan 2 - Biogen will use MorphoSys' Human Combinatorial Antibody Library technology to validate drug targets in its genomics programs, MorphoSys announced Tuesday.

Under the terms of the agreement, Biogen will pay MorphoSys an upfront technology access fee and  for use of MorphoSys' HuCAL technology for generating antibodies against expressed sequence tags, and will provide its own R & D funding. Biogen will make milestone and royalty payments to MorphoSys for any antibody-based therapeutics developed.

Financial terms of the agreement were not disclosed.

" This collaboration highlights the power of the MorphoSys technologies as tools for genomics-driven pharmaceutical discovery," Simon Moroney, MorphoSys CEO, said in a statement. " This deal is yet another example of our strategy of leveraging HuCAL as a tool to accelerate the identification of new targets. "

MorphoSys’ HuCAL technology produces synthetic human antibodies used in drug discovery. The company has licensing and research collaborations with Bayer, Roche AG, DuPont Pharmaceuticals, Millennium, Chiron, GPC Biotech AG, ProChon Biotech, Eos Biotechnology, and ImmunoGen.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.